Peapod Lane Capital LLC Buys 123,479 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Peapod Lane Capital LLC raised its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 37.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 452,060 shares of the company's stock after acquiring an additional 123,479 shares during the period. Atea Pharmaceuticals comprises approximately 1.5% of Peapod Lane Capital LLC's investment portfolio, making the stock its 26th largest holding. Peapod Lane Capital LLC owned 0.53% of Atea Pharmaceuticals worth $1,352,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the stock. Bank of America Corp DE raised its stake in shares of Atea Pharmaceuticals by 23.3% during the 4th quarter. Bank of America Corp DE now owns 73,441 shares of the company's stock worth $246,000 after purchasing an additional 13,902 shares during the period. BNP Paribas Financial Markets purchased a new stake in Atea Pharmaceuticals in the 4th quarter worth about $323,000. D. E. Shaw & Co. Inc. increased its holdings in Atea Pharmaceuticals by 32.3% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 256,083 shares of the company's stock worth $858,000 after acquiring an additional 62,505 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Atea Pharmaceuticals by 5.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 73,883 shares of the company's stock worth $248,000 after acquiring an additional 3,882 shares during the last quarter. Finally, Squarepoint Ops LLC increased its holdings in Atea Pharmaceuticals by 223.3% in the 4th quarter. Squarepoint Ops LLC now owns 50,750 shares of the company's stock worth $170,000 after acquiring an additional 35,053 shares during the last quarter. 86.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on AVIR. Morgan Stanley decreased their price objective on Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating for the company in a report on Friday, April 11th. Wall Street Zen raised Atea Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd.

Atea Pharmaceuticals Trading Up 3.0%

Shares of AVIR opened at $3.76 on Thursday. The company has a market cap of $321.78 million, a PE ratio of -2.28 and a beta of 0.25. The stock has a 50-day moving average price of $3.13 and a 200-day moving average price of $3.09. Atea Pharmaceuticals, Inc. has a 12-month low of $2.46 and a 12-month high of $4.15.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.16. As a group, analysts predict that Atea Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Atea Pharmaceuticals Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.

Want to see what other hedge funds are holding AVIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.